<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92463">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01971554</url>
  </required_header>
  <id_info>
    <org_study_id>8666-003</org_study_id>
    <nct_id>NCT01971554</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)</brief_title>
  <official_title>A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Type 2 Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics
      (PD) of MK-8666 in participants with type 2 diabetes mellitus (T2DM).  Participants enrolled
      in this trial would be either treatment-naive or have washed off of oral anti-hyperglycemic
      agents.  MK-8666 is planned to be administered orally for up to 2 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in Fasting Plasma Glucose</measure>
    <time_frame>Baseline and Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced an Adverse Event (AE)</measure>
    <time_frame>Up to Day 29</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Treatment Due to an AE</measure>
    <time_frame>Up to Day 14</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from Time Zero to 24 Hours (AUC0-24h)</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Drug Concentration After Dosing (Cmax)</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Cmax (Tmax)</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>MK-8666 (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8666, Dose 1, oral, once a day (QD) for Days 1 to 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8666 (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8666, Dose 2, oral, QD, for Days 1 to 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8666 (Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8666, Dose 3, oral, QD for Days 1 to 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo corresponding to MK-8666 doses, oral, QD for Days 1 to 14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8666</intervention_name>
    <description>MK-8666, capsules, oral, QD, Days 1 to 14</description>
    <arm_group_label>MK-8666 (Dose 1)</arm_group_label>
    <arm_group_label>MK-8666 (Dose 2)</arm_group_label>
    <arm_group_label>MK-8666 (Dose 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, capsules, oral, QD, Days 1 to 14</description>
    <arm_group_label>MK-8666 (Dose 1)</arm_group_label>
    <arm_group_label>MK-8666 (Dose 2)</arm_group_label>
    <arm_group_label>MK-8666 (Dose 3)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  If female, must be either postmenopausal or surgically sterile

          -  A Body Mass Index (BMI) ≥18 kg/m^2 to ≤40 kg/m^2, inclusive.

          -  A diagnosis of T2DM

          -  Drug naïve or is being treated with no more than 2 oral antihyperglycemic agents
             (thiazolidenediones are excluded)

          -  Judged to be in good health except for T2DM

          -  Willing to follow a standard weight maintaining diet throughout the study

          -  A nonsmoker or has not used nicotine or nicotine-containing products for at least 3
             months

        Exclusion Criteria:

          -  A history of clinically significant endocrine (except T2DM), gastrointestinal,
             cardiovascular, hematological, hepatic, immunological, renal, respiratory, or
             genitourinary abnormalities or diseases

          -  A history of myositis or complaints including diffuse myalgias, muscle tenderness, or
             weakness.

          -  A history of cancer (malignancy) excepting adequately treated non-melanomatous skin
             carcinoma or carcinoma in situ of the cervix

          -  Has clinically unstable diabetic retinopathy, neuropathy, and/or clinical evidence of
             gastroparesis (frequent nausea, bloating or vomiting, severe gastroesophageal reflux,
             early satiety)

          -  A history of type 1 diabetes mellitus and/or history of ketoacidosis

          -  Taking a medication for a co-morbid condition that is not permitted during the study

          -  A history of significant multiple and/or severe allergies

          -  Positive for hepatitis B surface antigen, hepatitis C antibodies or human
             immunodeficiency virus

          -  Had major surgery, donated or lost 1 unit of blood within 4 weeks prior to study
             participation

          -  Participated in another investigational trial within 4 weeks prior to study
             participation

          -  Consumes excessive amounts of alcoholic or caffeine-containing beverages

          -  A regular user of illicit drugs or a history of drug or alcohol abuse within the past
             year
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>October 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
